conjugated compound

Abstract

The present invention relates to glycosphingolipid analogs and peptide derivatives thereof, which are useful in the treatment or prophylaxis of diseases or diseases associated eg with infections, atopic disorders, autoimmune diseases or cancer.

Description

technical field [0001] The present invention generally relates to certain glycosphingolipid analogs and peptide derivatives thereof, compositions comprising these compounds (including pharmaceutical compositions and adjuvant compositions), methods for preparing the compounds, and the use of these compounds A method of treating or preventing a disease or condition, especially a disease or condition associated with cancer, infection, atopic disorders, autoimmune disease or diabetes. Background technique [0002] Constant natural killer T cells (NKTs) are a subset of T cells associated with a variety of diseases. In some cases, they are able to enhance responses to infections (Kinjo, Illarionov et al., 2011) and cancer (Wu, Lin et al., 2011), and also have the ability to suppress autoimmune diseases (Hong, Wilson et al., 2001) and type II diabetes Ability. Activation of NKT cells can also lead to undesirable immune responses associated with allergy (Wingender, Rogers et al., ...

AI Technical Summary

Problems solved by technology

[0008] Although α-GalCer has considerable biological activity, it does have limitations, such as poor solubility (Ebensen, Link et al., 2007), lack of efficacy in human clinical trials (Giaccone, Punt et al., 2002), promoting T cell Anergy (Parekh, Wilson et al., 2005) and production of both Th1 and Th2 cytokines may cause mixed effects in model studies

Images